Compare SOPH & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOPH | EIC |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.3M | 228.8M |
| IPO Year | 2021 | 2018 |
| Metric | SOPH | EIC |
|---|---|---|
| Price | $8.17 | $9.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.50 | ★ $12.63 |
| AVG Volume (30 Days) | ★ 624.4K | 88.5K |
| Earning Date | 05-05-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 13.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $19.57 | N/A |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.21 | $9.17 |
| 52 Week High | $8.98 | $13.55 |
| Indicator | SOPH | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 35.30 |
| Support Level | $4.63 | $9.33 |
| Resistance Level | $8.98 | $10.14 |
| Average True Range (ATR) | 0.43 | 0.12 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 58.12 | 24.59 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.